Editorials

Methotrexate Therapy for Psoriatic Arthritis: Reappraisal of an Old Remedy
L.A. Saketkoo, R. Cuchacovich, L.R. Espinoza .......................... 369

Lessons from Magnetic Resonance Imaging Studies in Rheumatoid Arthritis M. Quinn ........................................... 372

Infections, Drugs, and Rheumatoid Arthritis. What Have We Learned? J.S. Coblyn ......................... 375

Diffuse Idiopathic Skeletal Hyperostosis: Time for a Change R. Mader .................................................. 377

Articles

Anemia in Early RA Is Associated with IL-6-Mediated Bone Marrow Suppression, But Has No Effect on Disease Course or Mortality
C. Nikolaisen, Y. Figenschau, J.C. Nossent ......................... 380


Etanercept Reduces Synovitis as Measured by MRI in Patients with Active RA After Only 6 Weeks M.P. Lisbona, J. Maymo, J. Perich, M. Almirall, C. Pérez-García, J. Carbonell ............................................. 394


Osteoclast Inhibitory Effects of Vitamin K, Alone or in Combination with Etidronate or Risedronate in Patients with RA: 2-Year Results M. Morishita, M. Nagashima, K. Wauke, H. Takahashi, K. Takenouchi .................................................. 407

Easy and Accurate Diagnosis of RA Using Anti-CCP2 Antibody, Swollen Joint Count, and CRP/RF T. Yamane, A. Hashiramoto, Y. Tanaka, et al ......................... 414

Short-Term Course of Chronic Hepatitis B and C Under Treatment with Etanercept Associated with Different DMARD without Antitumor Prophylaxis D.U. Cansu, T. Kalijoglou, C. Korkmaz ......................................... 421

IgM-RF, Anti-CCP, and Anti-Citrullinated Human Fibrogen Antibodies Decrease During Treatment with the TNF Blocker Infliximab in Patients with RA M. Vis, W.H. Bos, G. Wolbink, et al ............................ 425


DM and PM Associated with Malignancy: A 21-year Retrospective Study C. András, A. Ponyi, T. Constantin, et al .................................. 438

Epidemiology of Sporadic Inclusion Body Myositis and PM in Olmsted County, Minnesota F.C. Wilson, S.R. Ytterberg, J.L. St. Sauver, A.M. Reed .................................................. 445

Relsaps in Patients with ANCA-Associated Vasculitis: Likely to Begin with the Same Organ as Initial Onset M. Chen, F. Yu, M-H. Zhao .............................................. 448


Assessment of Pulmonary Arterial Hypertension in Patients with SSC: Comparison of Noninvasive Tests with Results of Right-Heart Catheterization V.M. Hsu, A.E. Moreyra, A.C. Wilson, et al ......................... 458

Does Incorporation of Aids and Devices Make a Difference in the Score of the HAQ-Disability Index? Analysis from a Scleroderma Clinical Trial D. Khanna, P.J. Clements, A.E. Postlethwaite, D.E. Furst, for the Scleroderma Collagen Type 1 Study Group .............................................. 466

Reappraisal of the Effectiveness of MTX in PsA: Results from a Longitudinal Observational Cohort V. Chandran, C.T. Schentag, D.D. Gladman ........................................ 469

Treatment of PsA and RA with Disease Modifying Drugs — Comparison of Drugs and Adverse Reactions P.S. Hellinew, W.J. Taylor for the CASPAR Study Group .......................... 472

Does We Really Need to Evaluate Entire Cervical Spines for Squaring Score in Modified Stoke AS Spinal Score? T-J. Kim, H-S. Kim, K-B. Joo, S. Kim, T-H. Kim .................................. 477

A Comparison of Self-reported Joint Symptoms Following Infection with Different Enteric Pathogens: Effect of HLA-B27 P. Schiellerup, K.A. Krogefalt, H. Locht ................................. 480

Efficacy and Tolerability of IV Ibandronate Injections in Postmenopausal Osteoporosis: 2-Year Results from the DIVA Study J.A. Eisman, R. Civitelli, S. Adami, et al .............................. 488

Gout in Ambulatory Care Settings in the US E. Krishnan, D. Lienesch, C.K. Kwok ........................................ 498

Contents continued opposite inside back cover . . .
## A Randomized, Double-blind, Placebo-Controlled, Phase III Trial of Pregabalin in the Treatment of Patients with FM


Page 502

## Pediatric Rheumatology

### IL-17 Levels Are Increased in JIA Synovial Fluid and Induce Synovial Fibroblasts to Produce Proinflammatory Cytokines and MMP

S. Agarwal, R. Misra, A. Aggarwal

Page 515

### Indications for a Disturbed Peripheral T-Cell Homeostasis in JIA: Absent Expansion of CD28– T-Cells and No Decrease of Naive T-Cells in CMV-positive Patients with JIA


Page 520

## Images in Rheumatology

### Ossification of the Posterior Longitudinal Ligament

R.H. Andres, R. Binggeli

Page 528

### Bone Marrow Histology in a Patient with Fever of Unknown Origin

A. Holbro, S. Dirnhofer, P. Went, A. Tyndall, T. Daikeler

Page 530

## Case Series

### New Onset of Crohn’s Disease During Treatment of Active AS with Etanercept


Page 532

### Alendronate-Induced Synovitis

D.P. Gwynne Jones, R.L. Savage, J. Highton

Page 537

## Correspondence

### Intrinsic Muscle Spasm of the Hand: Bunnell’s Sign

H. Ishikawa

Page 539

### Reply

T. Taylor

Page 539

## Letters

### Systemic Nocardiosis in a Case of RA Treated with TNF Blockers

D. Wendling, M. Murad, S. Mathieu, E. Berger, L. Rumbach

Page 539

### Nocardia Infection with Adalimumab in RA

V.A. Doraiswamy

Page 542

### Prevalence of Patello- and Tibiofemoral OA in Elva, Southern Estonia

A. Tamm, M. Lintrop, K. Veske, Ü. Hansen, A. Tamm

Page 543

### Rapid Response of Nail Psoriasis to Etanercept

E. Rallis, E. Stavropoulou, D. Rigopoulos, C. Verros

Page 544

## Correction

### Polymorphisms in Genes Encoding Tumor Necrosis Factor-α and HLA-DRB1 Are Not Associated with Response to Infliximab in Patients with Rheumatoid Arthritis

J.A. Pinto, I. Rego, C. Fernandez-López, M. Freire, J.L. Fernandez-Sueiro, F.J. Blanco, M. Rodríguez-Gómez, R. Sanmarti, J.D. Cañete

Page 546

## Meetings in Rheumatology